Bonn University supports research staff in stem cell furore
This article was originally published in Clinica
Executive Summary
The University of Bonn has dismissed criticism of two members of its staff, Professor Otmar Wiestler and Dr Oliver Brustle, who had voiced the hope of being able to import embryonic stem cells for research purposes (see Clinica No 962, p 5). In a public debate last week, the board of the faculty of medicine acknowledged that a factual discussion on research into both adult and embryonic stem cells was a necessity, but that personal attacks on its staff members were "unwarranted and discriminatory".
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.